Statins and hemoperfusion improve 28-day survival in septic shock patients

Central European Journal of Medicine, 04/27/2012

The present study suggests that pre–existing statin use and hemoperfusion with polymyxin B–immobilized fiber (PMX–F) may separately and independently contribute to blunt the process of septic shock.


  • The authors examined retrospectively whether pre–existing statin and hemoperfusion with PMX–F at the time of admission were separately and independently associated with decreased overall 28–day mortality in septic shock patients.
  • Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study.
  • All patients underwent a complete history and physical examination, determination of blood chemistries.


  • Multiple stepwise regression analysis revealed that albumin, creatinine (inversely), statin use, hemoperfusion with PMX–F and HDL–cholesterol were independently correlated to 28–day survival in septic shock patients (R2=0.464).

Print Article Summary Cat 2 CME Report